title: Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome.
abstract: To determine whether bucolome (5-n-butyl-1-cyclohexyl-2,4,6-trioxoperhydropyrimidine), a nonsteroidal anti-inflammatory agent, can reverse diuretic resistance of furosemide in patients with nephrotic syndrome, we examined the inhibitory effect of bucolome on the protein binding of furosemide in serum and urine. Bucolome significantly inhibited the protein binding of furosemide not only in serum but also in urine of preparation albumin (UPA), which mimics urinary albumin concentration in patients with nephrotic syndrome by ultrafiltration method. The binding percentage of furosemide to albumin was approximately 70% in UPA. With coadministration of bucolome to healthy volunteers, renal clearance of furosemide was increased, reflecting the increase of the free fraction of furosemide in serum. Furthermore, coadministration of bucolome caused a significant increase of urine volume and sodium concentration in urine. Even at higher urine levels of furosemide, the inhibitory effect of bucolome on the protein binding of furosemide in UPA remains constant, and changes in pH at weakly acidic pH levels (pH 5.5-6.5) did not alter the inhibitory effect of bucolome. Interestingly, coadministration of bucolome with furosemide in doxorubicin (Adriamycin)-induced nephrotic syndrome model rats alleviated the diuretic resistance. These results suggest that bucolome has a potent inhibitory effect on the protein binding of furosemide in the urine and can partially restore the diuretic response of furosemide in patients with nephrotic syndrome by increasing the free fraction of furosemide at the site of action.
authors.affiliation: Department of Pharmacy, Miyazaki Medical College Hospital, Miyazaki, Japan.
authors.forename: Norito
authors.initials: N
authors.lastname: Takamura
authors.forename: Toru
authors.initials: T
authors.lastname: Maruyama
authors.forename: Etsuo
authors.initials: E
authors.lastname: Chosa
authors.forename: Keiichi
authors.initials: K
authors.lastname: Kawai
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Tsutsumi
authors.forename: Yukie
authors.initials: Y
authors.lastname: Uryu
authors.forename: Keishi
authors.initials: K
authors.lastname: Yamasaki
authors.forename: Tsuneo
authors.initials: T
authors.lastname: Deguchi
authors.forename: Masaki
authors.initials: M
authors.lastname: Otagiri
mesh_terms: D000328:Adult; D000418:Albumins / Q000737:chemistry; D000419:Albuminuria / Q000378:metabolism; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001463:Barbiturates / Q000494:pharmacology*; D001798:Blood Proteins / Q000378:metabolism; D004232:Diuretics / Q000493:pharmacokinetics* / Q000494:pharmacology*; D004317:Doxorubicin; D004351:Drug Resistance; D005665:Furosemide / Q000493:pharmacokinetics* / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects; D009404:Nephrotic Syndrome / Q000139:chemically induced / Q000378:metabolism* / Q000652:urine; D011485:Protein Binding; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000418:Albumins; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001463:Barbiturates; D001798:Blood Proteins; D004232:Diuretics; D005665:Furosemide; D004317:Doxorubicin; C084817:bucolome